Key result
Serum salusin-β levels were significantly elevated in paediatric patients with chronic kidney disease compared to healthy controls (p=0.014), but not in those with hypertension.
Why the study?
Because atherosclerosis can begin in childhood, salusin-beta holds promise as a cardiovascular risk biomarker; researchers sought to evaluate its levels in children with early chronic kidney disease or hypertension versus healthy controls.
Are serum salusin-β levels elevated in pediatric patients with chronic kidney disease or hypertension compared to healthy controls, and do they correlate with pulse wave velocity?
Cross-Sectional (n=129)
Are serum salusin-β levels elevated in pediatric patients with chronic kidney disease or hypertension compared to healthy controls, and do they correlate with pulse wave velocity?
p-value: p=0.014
Salusin-β levels are elevated in pediatric patients with CKD and weakly correlate with pulse wave velocity, suggesting a potential role as a biomarker for cardiovascular risk assessment.
Salusin-β elevation may mark pediatric CKD but not hypertension; cross-sectional data leave open its diagnostic role and require prospective validation.
PURPOSE: Salusins are newly identified endogenous peptides implicated in the atherosclerotic process. Salusin-β, in particular, is recognized for its proatherogenic role. Given that atherosclerosis can commence in childhood, salusin-β holds promise as a potential biomarker for cardiovascular risk assessment. The objective of our study was to investigate salusin-β levels in children with early stages of chronic kidney disease (CKD) or hypertension (HTN), and compare them to healthy controls. Furthermore, we aimed to evaluate its association with obesity and pulse wave velocity (PWV), the latter being a well-established marker for determining arterial elasticity. MATERIALS AND METHODS: This cross-sectional study involved 96 paediatric patients, including 46 with CKD and 50 with HTN, as well as 33 healthy controls. Anthropometric measurements, PWV assessments, serum salusin-β values, and basic laboratory investigations were conducted for all participants. RESULTS: Salusin-β levels were found to be elevated in patients with CKD (p = 0.014), but not in patients with HTN when compared to healthy controls. When correlating salusin-β levels with PWV, a significant but weak correlation was observed (r = 0.211, p = 0.020). CONCLUSIONS: Salusin-β levels were elevated in paediatric patients with CKD. Additionally, salusin-β levels correlated significantly with PWV. Obesity played a smaller role in these correlations, with significant correlations observed only after combining cardiovascular risk factors revealing certain associations between salusin-β levels and some cardiovascular variables, but with inconclusive findings and, in some instances, even contrary to anticipated outcomes.
No takes yet. Share an insight, caveat, or question.
Močnik et al. (2025) conducted a cross-sectional in Chronic kidney disease or hypertension (n=129). Chronic kidney disease or hypertension vs. Healthy controls was evaluated on Serum salusin-β levels (p=0.014). Serum salusin-β levels were significantly elevated in paediatric patients with chronic kidney disease compared to healthy controls (p=0.014), but not in those with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: